Literature DB >> 28540748

Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.

Dalia Abdel-Raouf Salem1,2, Neha Korde3, David J Venzon4, David J Liewehr4, Irina Maric5, Katherine R Calvo5, Raul Braylan5, Prashant R Tembhare6, Constance M Yuan7, Carl Ola Landgren3, Maryalice Stetler-Stevenson7.   

Abstract

IL-6 activity in normal plasma cells (nPCs) and abnormal plasma cells (aPCs) is CD126 (subunit of IL-6 receptor) dependent. We quantified CD126 expression on nPCs and aPCs in monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and multiple myeloma (MM). CD126 was detected on all nPCs and aPCs indicating that CD126 does not have diagnostic utility. CD126 expression was higher in aPCs than in nPCs in 85% SMM but only 41% MGUS and there was evidence that CD126 was higher in aPCs than nPCs in the SMM (p = .048) but not MGUS (p = .96) patients. There is also a greater association between nPC and aPC CD126 expression in low risk MGUS than observed in high risk MGUS and SMM, suggesting normal regulation of CD126 decreases with disease progression. Future studies need to elucidate the role of bone marrow milieu versus escape from normal CD126 regulation in malignant transformation of clonal plasma cells.

Entities:  

Keywords:  CD126; IL-6 receptor; MGUS; flow cytometry; smoldering myeloma

Mesh:

Substances:

Year:  2017        PMID: 28540748      PMCID: PMC6193452          DOI: 10.1080/10428194.2017.1321746

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  37 in total

1.  Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

Authors:  Jesús F San Miguel; Julia Almeida; Gema Mateo; Joan Bladé; Consuelo López-Berges; Dolores Caballero; José Hernández; María Jesús Moro; Javier Fernández-Calvo; Joaquín Díaz-Mediavilla; Luis Palomera; Alberto Orfao
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

2.  The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.

Authors:  A C Rawstron; J A Fenton; J Ashcroft; A English; R A Jones; S J Richards; G Pratt; R Owen; F E Davies; J A Child; A S Jack; G Morgan
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Variables affecting the quantitation of CD22 in neoplastic B cells.

Authors:  Gregory A Jasper; Indu Arun; David Venzon; Robert J Kreitman; Alan S Wayne; Constance M Yuan; Gerald E Marti; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2010-09-24       Impact factor: 3.058

Review 4.  Molecular regulation of B lymphocyte response.

Authors:  T Kishimoto; T Hirano
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

5.  Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Authors:  Sally A Hunsucker; Valeria Magarotto; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Donna M Weber; Sheeba K Thomas; Jatin J Shah; Peter M Voorhees; Hong Xie; Mark Cornfeld; Jeffrey A Nemeth; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2011-01-17       Impact factor: 6.998

6.  Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Authors:  Maria Arroz; Neil Came; Pei Lin; Weina Chen; Constance Yuan; Anand Lagoo; Mariela Monreal; Ruth de Tute; Jo-Anne Vergilio; Andy C Rawstron; Bruno Paiva
Journal:  Cytometry B Clin Cytom       Date:  2015-06-02       Impact factor: 3.058

7.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

8.  Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jose J Pérez; Gema Mateo; Maria Angeles Montalbán; Maria Victoria Mateos; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

View more
  2 in total

1.  Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.

Authors:  Dalia A Salem; Irina Maric; Constance M Yuan; David J Liewehr; David J Venzon; James Kochenderfer; Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2018-07-18       Impact factor: 3.156

Review 2.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.